- In November 2024, Bayer and Cytokinetics, Incorporated announced, they have entered into a collaboration and license agreement for the exclusive development and commercialization of aficamten in Japan, subject to certain reserved development rights of Cytokinetics for the potential treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM)
- In November 2024, Eli Lilly and Company announced positive Phase 2 results for muvalaplin, an orally administered selective inhibitor of lipoprotein aimed at treating heart disease. The study showed that muvalaplin significantly lowered elevated lipoprotein levels in adults, achieving its primary endpoint of a percent change in lipoprotein levels from baseline to week 12
- In October 2024, Abbott announced a new, first-of-its-kind clinical trial designed to improve outcomes in patients with worsening heart failure who could benefit from advanced therapy options. The TEAM-HF trial, which is planned to enroll up to 850 patients across 75 sites worldwide, will measure pulmonary artery pressures (PAP) using Abbott's CardioMEMS™ HF System to objectively identify advanced heart failure patients at high risk of mortality who could benefit from a life-saving HeartMate 3™ left ventricular assist device (LVAD, or heart pump) earlier in their disease progression
- In October 2024, AstraZeneca signed an exclusive licensing agreement with CSPC Pharmaceutical Group Ltd. (CSPC) to advance the development of an early-stage, innovative small molecule Lipoprotein (a) (Lp(a)) disruptor. This compound holds promise for providing additional benefits to patients with dyslipidemia. The partnership enhances AstraZeneca's cardiovascular portfolio, aiming to address key risk factors that contribute to chronic cardiovascular diseases
- In April 2024, Boehringer Ingelheim announced results from EMPACT-MI phase III trial investigating the effect of Jardiance (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack. The clinical trial showed a 10% relative risk reduction in the primary composite endpoint of time to first hospitalization due to heart failure
